BA Sciences’ Post

I'm pleased to present our annual report for the biotechnology, pharmaceuticals, and healthcare industry for the year 2023, as you can find at www.motitus.com. This report provides insights into the latest trends, challenges, and opportunities in the industry, as well as a comprehensive analysis of the most significant developments in drug approvals, clinical trials, mergers and acquisitions, and regulatory policies. One of the most notable milestones in biotechnology & and pharmaceutical drugs during this period was the approval of several groundbreaking therapies. In January 2023, the FDA approved a new gene therapy for spinal muscular atrophy (SMA), called Zolgensma-2, which is an improvement over the previous version of Zolgensma. In January 2023 FDA granted Leqembi accelerated approval and traditional approval in July 2023. Lecanemab (Leqembi) is a monoclonal antibody medication used for the treatment of Alzheimer's disease. In February 2023 FDA approved Jesduvroq tablets as the first oral treatment for anemia (decreased number of red blood cells) caused by chronic kidney disease for adults who have been receiving dialysis for at least four months. In July 2023, the FDA approved the Label Expansion of Trikafta for cystic fibrosis for young children. In December 2023, the FDA approved Fabhalta (iptacopan) as the first oral monotherapy for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) These are just some of the most significant milestones in biotechnology and pharmaceutical drugs during this period. Our consulting firm's annual review provides more detailed insights into these developments as well as other trends and challenges facing the biotechnology, pharmaceutical and healthcare industry today. www.motitus.com #annualreport #pharmaceuticals #biotechnology #annualreview #healthcare #motitus https://lnkd.in/dNvXnBS7

Annual Review We welcome 2024 and as an innovative consulting firm specializing in biotechnology, pharmaceuticals and healthcare, we are proud to present our annual report for the year 2023. This report highlights the significant advancements and transformative innovations that have shaped the industry over the past year. With a focus on cutting-edge research, groundbreaking therapies, and emerging trends, our report provides insights into the current state of the industry and its future trajectory. As we continue to navigate the complex and rapidly evolving landscape of biotechnology, pharmaceuticals, and healthcare, our commitment to delivering innovative solutions and strategic guidance remains unwavering. We invite you to join us as we explore the latest developments in this dynamic and exciting field and to walk together the 2024 by bulding success. www.motitus.com #annualreview #pharmaceuticals #biotechnology #healthcare #annualreport

CQDM. We celebrate. 15th anniversary of CQDM. In 2017, CQDM is launching SynergiQc, which will become its flagship program and will stimulate industrial research carried out in collaboration with the academic community in the biopharmaceutical field. The program, supported by the Government of Quebec, makes Quebec SMEs more competitive and productive and helps them invest earlier in research and development, in addition to generating positive economic benefits for the province in its entirety. Since the creation of SynergiQc, 48 projects have been financed by companies that have developed new innovations and more than 140 partners have been involved. Examples include the successes of NMX Research and Solutions Inc, Theratechnologies Inc. and Immune Biosolutions inc. See how CQDM has been ''Facilitating biopharma innovation'' since 2008 by consulting our website, including the section dedicated to our 15th anniversary: https://lnkd.in/gX-jtJig #lifesciences #biotechnology #drugdevelopment #innovation #funding #projects #medical #research #intelligenceartificielle #artificialintelligence #pharmaceutique #pharmaceutical #biopharma #biopharmaceutical #rna #rnatherapeutics #arn #faciliterinnovationbiopharma #anniversaire #anniversary

I invite Canadian 🇨🇦 companies to submit their comments of the draft sector guidance on #biotechnology and #pharmaceuticals of the Taskforce on Nature-related Financial Disclosures (TNFD). By better understanding their dependencies and impacts on #nature , #business can play an important role in addressing the global #biodiversityloss crisis. #fornature

Industry-academia partnerships must navigate differences in organizational structures and overall goals—disparate publication objectives, for example. Ben Siddall and John Barbadoro of Vantage Partners moderated a spirited discussion about whether it is better to utilize a decentralized or centralized model for managing these types of collaborations in the latest ASAP webinar. https://lnkd.in/gUMvXm67 #alliancemanagement #alliances #strategicalliances #alliancemanagers #collaboration #strategicpartnerships #tech #ITindustry #IT #hightech #pharmaceutical #pharmaceuticalindustry #biopharma #biotech #biotechnology #biotechindustry #academicresearch #academia #drugdiscovery

Lonza has successfully completed the acquisition of the Genentech large-scale biologics manufacturing site in Vacaville, California, from Roche. This USD 1.2 billion deal adds a significant 330,000-liter bioreactor capacity to 𝐋𝐨𝐧𝐳𝐚'𝐬 𝐦𝐚𝐦𝐦𝐚𝐥𝐢𝐚𝐧 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐢𝐧𝐠 𝐩𝐨𝐫𝐭𝐟𝐨𝐥𝐢𝐨, bolstering its West Coast presence. Positioned near San Francisco's biotech hub, the site complements Lonza’s growing network of facilities worldwide, including the East Coast and international locations. With over 750 skilled colleagues joining Lonza, this acquisition will help meet the increasing demand for commercial #biologicsmanufacturing. 🔗 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐭𝐡𝐢𝐬 𝐞𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐞𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧: https://lnkd.in/emZYParC #Lonza #biologics #vacaville #manufacturing #healthcare #biotech #pharma #innovation #growth #mammalianmanufacturing #roche #sanfrancisco #pharmamanufacturing #biopharma #vacavilleexpansion

Draft sector guidance - Biotechnology and pharmaceuticals The TNFD invites organisations and stakeholders across the biotechnology and pharmaceutical sectors to provide feedback on the guidance currently open for market consultation. ⏲️Deadline to submit feedback - 29th March 2024. Feedback is welcome from all types of companies, financial institutions, business associations, scientific and academic institutions, NGOs and other interested stakeholders. 💊Draft sector guidance – Biotechnology and pharmaceuticals 🔗 https://ow.ly/muU250QH3bI Feedback on how to improve the guidance, whether the proposed sector metrics are decision-useful and proportionate, and any suggestions for additional metrics are particularly welcomed. 🔍Discussion paper on conducting advanced scenario analysis 🔗https://ow.ly/bKz350QH3bK This paper looks at approaches and practical examples to conduct advanced (quantitative) scenarios for financial institutions and large corporations. Feedback on the proposed approach and how it could be improved is particularly welcome. The TNFD looks forward to receiving your feedback and contributions to the ongoing development of the TNFD guidance. #TNFD #pharmaceutical #sustainability

🚀 Exciting news in the pharmaceutical and biotechnology industries! 🧬 The High Throughput Screening Market is projected to grow rate at a ~8.5% by 2029. This surge is fueled by various factors such as the increasing demand for novel drug discovery, advancements in screening technologies, and rising investments in R&D. Unlock valuable market insights to download sample report: https://lnkd.in/dzjTrkW4 With key players like Agilent Technologies, Bio-Rad Laboratories, Merck Group, PerkinElmer, Thermo Fisher Scientific, Beckman Coulter Diagnostics, BMG LABTECH, Tecan, Hamilton Company, BioTek Instruments, Charles River Laboratories, Sygnature Discovery, Molecular Devices, Eurofins Scientific Finland Oy, and Evotec, and more leading the charge, the competition is fierce and innovation is at its peak. Stay ahead of the curve and tap into the future of drug discovery. #HighThroughputScreening #Pharma #Biotech #Innovation #DrugDiscovery #PrecisionMedicine #HTS #PharmaceuticalResearch #Biotechnology #Pharmaceutical #PersonalizedMedicine #AutomationInScience #HighContentScreening #FunctionalScreening #CancerImmunotherapy #ResearchChallenges #NorthAmerica #AsiaPacificMarket

We'd like to say a huge thank you to all of our presenters, facilitators and all of you who joined our Oligonucleotide Therapeutics Roundtable Xchange in #SanDiego, February 28th. If you missed it, join us next time and take advantage of this unique highly interactive meeting format designed for maximum engagement and collaboration with your peers. For more information or to view full agendas of the upcoming roundtable meetings and secure your spot, please visit https://lnkd.in/djSEqbRU Please note: Registration is only open to Senior Scientists and above actively working in the #pharmaceutical / #biotech industry. Each roundtable is limited to 8 participants. #hubXchangeNotAConference #lifesciences #pharma #pharmaceutical #pharmacology #biotech #biotechnology #biotechnews #oligonucleotides #therapeutics #development #manufacturing #drugdevelopment #drugdiscovery #drugdelivery #drugspharmaceuticals #drugproduct #drugmanufacturing #drugsubstance

🔍 Spotlight on #Pharma #Partnerships in #TechBio: Showcasing Pfizer In the ever-evolving world of biotechnology, partnerships are the driving force behind groundbreaking innovations. Pfizer, a global leader in the biopharmaceutical industry, exemplifies this spirit of collaboration. 🌐 Pfizer's TechBio Collaborations Among 115 disclosed partnerships worldwide, Pfizer has strategically focused 32 on the TechBio sector. These alliances underscore Pfizer's commitment to integrating cutting-edge technology with biological research to develop pioneering therapies. 📊 Geographic Distribution of Pfizer's TechBio Partnerships: - 66% with US ventures - 19% with Asia-Pacific ventures - Only 6% with European ventures This distribution highlights Pfizer's strong focus on the US market while recognizing the growing innovation landscapes in Asia-Pacific and Europe. 🔬 Venture Maturity Insight: The average alpha score, which indicates the maturity of Pfizer's TechBio portfolio, is a notable 69.8. This score reflects the advanced development stage and significant potential of the ventures within Pfizer's collaborative network. #drugdiscovery #omics #bioinformatics